Jentadueto

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Jentadueto (Metformin Hydrochloride, Linagliptin)

Q: What is Jentadueto used for?

Jentadueto is prescribed to adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise. It combines metformin, which improves insulin sensitivity, with linagliptin, which enhances insulin secretion, to help achieve better glycaemic control.

Q: How does Metformin Hydrochloride work?

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity, allowing the body to use glucose more efficiently. This action lowers fasting blood glucose levels and contributes to overall glycaemic control.

Q: What is the usual dose of Jentadueto?

The specific dose of Jentadueto is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Q: Is Jentadueto safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

Q: How do I order Jentadueto from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Jentadueto compare with other antidiabetic therapies?

Jentadueto offers a fixed‑dose combination of metformin and linagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in a single tablet. This can simplify regimens compared with taking separate agents and may improve adherence versus multiple‑pill therapies.

Q: What are the storage requirements for Jentadueto?

Store Jentadueto tablets at ambient temperature, below 25 °C, in the original container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Q: How is Jentadueto administered?

Jentadueto is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not split, crushed, or chewed unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with Jentadueto?

The most serious risks include lactic acidosis (related to metformin) and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of renal or hepatic impairment, which can increase these risks.

Q: Who should not use Jentadueto?

Jentadueto is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or linagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Metformin Hydrochloride and Linagliptin, the active ingredient in Jentadueto, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus, used together with diet and exercise to improve glycaemic control in adult patients.

GNH India supplies Jentadueto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. All batches meet EU pharmacopeial standards and are shipped under controlled conditions. The product is available for bulk and individual orders.

Manufacturer / TM Owner

Boehringer Ingelheim International Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jentadueto is an oral antidiabetic medication used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise.
Inadequate control with metformin alone: adds DPP‑4 inhibition to achieve target HbA1c.
Adjunct to lifestyle therapy: used as part of a comprehensive treatment plan for adult patients.

How It Works

Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels and glucose‑dependent insulin secretion, together providing complementary glucose‑lowering effects.

Side Effects

Jentadueto may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhea: frequent loose stools, usually transient.
Abdominal discomfort: cramping or pain.
Headache: mild tension‑type headache.
Mild hypoglycaemia: when combined with insulin or sulfonylureas.
Metallic taste: occasional alteration in taste perception.

Serious or Rare Side Effects

Lactic acidosis: rare but life‑threatening metabolic disturbance.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe hypersensitivity: rash, angioedema, or anaphylaxis.
Hepatic failure: signs of liver dysfunction.
Renal impairment worsening: especially in patients with pre‑existing kidney disease.
Acute kidney injury: sudden decline in renal function.

Precautions & Warnings

Before initiating Jentadueto, clinicians should consider several safety aspects.

Renal function assessment: evaluate eGFR and monitor periodically.
Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
Hypoglycaemia monitoring: especially when used with insulin or sulfonylureas.
Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
Drug interaction review: check concomitant medicines that affect renal clearance or DPP‑4 activity.
Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Jentadueto can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk.
Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
Iodinated contrast agents: risk of metformin‑associated lactic acidosis; discontinue metformin before imaging.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: increased risk of hypoglycaemia.
Diuretics (especially thiazides): may affect renal function and metformin clearance.
Rifampin: may reduce linagliptin plasma concentrations, decreasing efficacy.

Frequently Asked Questions

Jentadueto is prescribed to adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise. It combines metformin, which improves insulin sensitivity, with linagliptin, which enhances insulin secretion, to help achieve better glycaemic control.

Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity, allowing the body to use glucose more efficiently. This action lowers fasting blood glucose levels and contributes to overall glycaemic control.

The specific dose of Jentadueto is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Jentadueto offers a fixed‑dose combination of metformin and linagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in a single tablet. This can simplify regimens compared with taking separate agents and may improve adherence versus multiple‑pill therapies.

Store Jentadueto tablets at ambient temperature, below 25 °C, in the original container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Jentadueto is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not split, crushed, or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis (related to metformin) and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of renal or hepatic impairment, which can increase these risks.

Jentadueto is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or linagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.